Updating results

2725 results

Sort: Relevance | Date

Hormone-sensitive metastatic prostate cancer: docetaxel (ESUOM50)

Summary of the evidence on docetaxel for treating hormone-sensitive metastatic prostate cancer to inform local NHS planning and decision-making

Evidence summary Published January 2016

Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)

Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making

Evidence summary Published June 2016

Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)

Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making

Evidence summary Published June 2016

Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)

Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making

Evidence summary Published May 2016

Chronic obstructive pulmonary disease: tiotropium/olodaterol (Spiolto Respimat) (ESNM72)

Summary of the evidence on tiotropium/olodaterol (Spiolto Respimat) for treating chronic obstructive pulmonary disease (COPD)..

Evidence summary Published May 2016

Moderate to severe acute post­-operative pain: sufentanil sublingual tablet system (ESNM71)

Summary of the evidence on the sufentanil sublingual tablet system for treating post­operative pain to inform local NHS planning and decision-making

Evidence summary Published March 2016

Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release (ESNM70)

Summary of the evidence on guanfacine prolonged-release for attention deficit hyperactivity disorder (ADHD) to inform local NHS planning and decision-making

Evidence summary Published March 2016

Partial-onset seizures in epilepsy: perampanel as adjunctive treatment (ESNM7)

Summary of the evidence on perampanel for partial-onset seizures in epilepsy (in people aged 12 and over) to inform local NHS planning and decision-making

Evidence summary Published December 2012

Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)

Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making

Evidence summary Published March 2016

Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream (ESNM68)

Summary of the evidence on ivermectin 10 mg/g cream for treating papulopustular rosacea to inform local NHS planning and decision-making

Evidence summary Published January 2016

Restless legs syndrome: Oxycodone/naloxone prolonged release (ESNM67)

Summary of the evidence on oxycodone/naloxone prolonged release for treating restless leg syndrome (RLS) to inform local NHS planning and decision-making

Evidence summary Published December 2015

External genital and perianal warts: green tea (Camellia sinensis) leaf extract 10% ointment (ESNM66)

Summary of the evidence on green tea (Camellia sinensis) leaf extract 10% ointment for treating external genital and perianal warts to inform local NHS planning

Evidence summary Published December 2015

Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM65)

Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 2 diabetes mellitus to inform local NHS planning and decision-making

Evidence summary Published December 2015

Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)

Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making

Evidence summary Published December 2015

Coronary revascularisation: Cangrelor (ESNM63)

Summary of the evidence on cangrelor for coronary revascularisation to inform local NHS planning and decision-making

Evidence summary Published November 2015

Type 1 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM62)

Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 1 diabetes mellitus to inform local NHS planning and decision-making

Evidence summary Published October 2015

Schizophrenia: omega-3 fatty acid medicines (ESUOM19)

Summary of the evidence on omega-3 fatty acid medicines for treating schizophrenia to inform local NHS planning and decision-making

Evidence summary Published September 2013

Promoting tolerance of enteral feeds in children and young people: domperidone (ESUOM18)

Summary of the evidence on domperidone to promote tolerance of enteral feeds in children and young people..

Evidence summary Published July 2013 Last updated September 2014

Hyperhidrosis: oral glycopyrronium bromide (ESUOM16)

Summary of the evidence on oral glycopyrronium bromide for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

Evidence summary Published July 2013

Hypersalivation: oral glycopyrronium bromide (ESUOM15)

Summary of the evidence on oral glycopyrronium bromide for treating hypersalivation (sialorrhoea) to inform local NHS planning and decision-making

Evidence summary Published July 2013

Chronic anal fissure: botulinum toxin type A injection (ESUOM14)

Summary of the evidence on botulinum toxin type A injection for treating chronic anal fissure to inform local NHS planning and decision-making

Evidence summary Published June 2013

Gastroparesis in adults: oral erythromycin (ESUOM13)

Summary of the evidence on oral erythromycin for gastroparesis (delayed stomach emptying) in adults to inform local NHS planning and decision-making

Evidence summary Published June 2013

Generalised anxiety disorder: quetiapine (ESUOM12)

Summary of the evidence on quetiapine monotherapy for treating generalised anxiety disorder (GAD) to inform local NHS planning and decision-making

Evidence summary Published May 2013

Induction of labour in late intrauterine fetal death: vaginal misoprostol (after oral mifepristone) (ESUOM11)

Summary of the evidence on vaginal misoprostol (after oral mifepristone) for induction labour in late intrauterine fetal death (IUFD)..

Evidence summary Published April 2013

Significant haemorrhage following trauma: tranexamic acid (ESUOM1)

Summary of the evidence on tranexamic acid for significant haemorrhage (bleeding) after trauma (major injury) to inform local NHS planning and decision-making

Evidence summary Published October 2012

Chronic obstructive pulmonary disease: glycopyrronium bromide (ESNM9)

Summary of the evidence on glycopyrronium bromide for treating chronic obstructive pulmonary disease (COPD) to inform local NHS planning and decision-making

Evidence summary Published January 2013

Chronic obstructive pulmonary disease: aclidinium bromide (ESNM8)

Summary of the evidence on aclidinium bromide for treating chronic obstructive pulmonary disease (COPD) to inform local NHS planning and decision-making

Evidence summary Published January 2013

Pre-exposure prophylaxis of HIV in adults at high risk: Truvada (emtricitabine/tenofovir disoproxil) (ESNM78)

Summary of the evidence on Truvada (emtricitabine/tenofovir disoproxil) for pre-exposure prophylaxis (PrEP) of HIV in adults at high risk

Evidence summary Published October 2016

Parkinson's disease with end-of-dose motor fluctuations: opicapone (ES9)

Summary of the evidence on opicapone for reducing end-of-dose motor fluctuations in Parkinson’s disease to inform local NHS planning and decision-making

Evidence summary Published March 2017

Narcolepsy with or without cataplexy in adults: pitolisant (ES8)

Summary on the evidence on pitolisant for treating narcolepsy with or without cataplexy to inform local NHS planning and decision-making

Evidence summary Published March 2017

Skin involvement in systemic sclerosis: rituximab (ES7)

Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making

Evidence summary Published March 2017

Parkinson's disease with motor fluctuations: safinamide (ES6)

Summary of the evidence on safinamide for treating Parkinson’s disease with motor fluctuations to inform local NHS planning and decision-making

Evidence summary Published February 2017

Severe sialorrhoea (drooling) in children and young people with chronic neurological disorders: oral glycopyrronium bromide (ES5)

Summary of the evidence on oral glycopyrronium bromide for severe sialorrhoea (drooling) in children and young people with chronic neurological disorders

Evidence summary Published February 2017

Refractory extrapulmonary sarcoidosis: infliximab (ES4)

Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making

Evidence summary Published January 2017

Oestrogen deficiency symptoms in postmenopausal women: conjugated oestrogens and bazedoxifene acetate (ES3)

Summary of the evidence on conjugated oestrogens and bazedoxifene acetate for oestrogen deficiency symptoms to inform local NHS planning and decision-making

Evidence summary Published December 2016

Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy (ES20)

Summary of the evidence on doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy in women aged 18 years and older to inform local NHS

Evidence summary Published June 2019

Pulmonary sarcoidosis: infliximab (ES2)

Summary of the evidence on infliximab for treating pulmonary sarcoidosis to inform local NHS planning and decision-making

Evidence summary Published December 2016

Opioid dependence: buprenorphine prolonged-release injection (Buvidal) (ES19)

Summary of the evidence on buprenorphine prolonged-release subcutaneous injection (Buvidal) for opioid dependence to inform local NHS

Evidence summary Published February 2019

Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) (ES18)

Summary of the evidence on fluticasone furoate, umeclidinium and vilanterol (Trelegy) for chronic obstructive pulmonary disease (COPD) to inform local NHS

Evidence summary Published June 2018

Chronic obstructive pulmonary disease: beclometasone, formoterol and glycopyrronium (Trimbow) (ES17)

Summary of the evidence on beclometasone, formoterol and glycopyrronium (Trimbow) for chronic obstructive pulmonary disease (COPD) to inform local NHS planning

Evidence summary Published May 2018

Antimicrobial prescribing: Ceftazidime/avibactam (ES16)

Summary of the evidence on ceftazidime/avibactam for complicated intra-abdominal and UTI infections and hospital-acquired pneumonia

Evidence summary: antimicrobial prescribing Published November 2017

Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates (ES15)

Summary of the evidence on adjuvant bisphosphonates for preventing recurrence or improving survival in people with early breast cancer

Evidence summary Published July 2017

Obese, overweight with risk factors: liraglutide (Saxenda) (ES14)

Summary of the evidence on liraglutide for managing obesity and overweight with risk factors in adults to inform local NHS planning and decision-making

Evidence summary Published June 2017

Preventing recurrence of Clostridium difficile infection: bezlotoxumab (ES13)

Summary of the evidence on bezlotoxumab for preventing the recurrence of Clostridium difficile (C difficile) infection

Evidence summary Published June 2017

Non-cystic fibrosis bronchiectasis: inhaled tobramycin (ES12)

ES12 Key points The content of this evidence summary

Evidence summary Published April 2017

Type 1 diabetes: insulin degludec (ESNM24)

Summary of the evidence on insulin degludec for treating type 1 diabetes to inform local NHS planning and decision-making

Evidence summary Published September 2013

Gouty arthritis: canakinumab (ESNM23)

Summary of the evidence on canakinumab for treating gouty arthritis (gout) to inform local NHS planning and decision-making

Evidence summary Published July 2013

Asthma: beclometasone/formoterol (Fostair) for maintenance and reliever treatment (ESNM22)

Summary of the evidence on beclometasone/formoterol (Fostair) for treating asthma to inform local NHS planning and decision-making

Evidence summary Published June 2013

Chronic obstructive pulmonary disease: fluticasone furoate plus vilanterol (ESNM21)

Summary of the evidence on fluticasone furoate plus vilanterol for treating chronic obstructive pulmonary disease (COPD)..

Evidence summary Published June 2013

Type 2 diabetes: alogliptin (ESNM20)

Summary of the evidence on alogliptin (a dipeptidyl peptidase-4 [DPP-4] inhibitor) for type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published May 2013 Last updated October 2014